CA2715266A1 - Inhibition and treatment of gastrointestinal biofilms - Google Patents

Inhibition and treatment of gastrointestinal biofilms Download PDF

Info

Publication number
CA2715266A1
CA2715266A1 CA2715266A CA2715266A CA2715266A1 CA 2715266 A1 CA2715266 A1 CA 2715266A1 CA 2715266 A CA2715266 A CA 2715266A CA 2715266 A CA2715266 A CA 2715266A CA 2715266 A1 CA2715266 A1 CA 2715266A1
Authority
CA
Canada
Prior art keywords
beta
alpha
biofilm
amount
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2715266A
Other languages
English (en)
French (fr)
Inventor
Stephen F. Olmstead
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ProThera Inc
Original Assignee
ProThera Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ProThera Inc filed Critical ProThera Inc
Publication of CA2715266A1 publication Critical patent/CA2715266A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
CA2715266A 2008-02-08 2009-02-09 Inhibition and treatment of gastrointestinal biofilms Abandoned CA2715266A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6518608P 2008-02-08 2008-02-08
US61/065,186 2008-02-08
PCT/US2009/033599 WO2009100456A2 (en) 2008-02-08 2009-02-09 Inhibition and treatment of gastrointestinal biofilms

Publications (1)

Publication Number Publication Date
CA2715266A1 true CA2715266A1 (en) 2009-08-13

Family

ID=40939056

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2715266A Abandoned CA2715266A1 (en) 2008-02-08 2009-02-09 Inhibition and treatment of gastrointestinal biofilms

Country Status (10)

Country Link
US (3) US20090202516A1 (enExample)
EP (1) EP2254591B1 (enExample)
JP (2) JP6047273B2 (enExample)
CA (1) CA2715266A1 (enExample)
DK (1) DK2254591T3 (enExample)
ES (1) ES2645062T3 (enExample)
NO (1) NO2254591T3 (enExample)
PL (1) PL2254591T3 (enExample)
PT (1) PT2254591T (enExample)
WO (1) WO2009100456A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0811530B1 (pt) 2007-05-14 2019-01-02 Research Foundation Of State Univ Of New York composição compreendendo indutor(es) de resposta fisiológica à dispersão ácido decanóico, superfície, solução, método ex vivo de tratamento ou inibição da formação de um biofilme sobre uma superfície
CA2720301C (en) * 2008-04-03 2017-11-07 Kane Biotech Inc. Dispersinb tm, 5-fluorouracil, deoxyribonuclease i and proteinase k-based antibiofilm compositions and uses thereof
WO2011037618A2 (en) * 2009-09-23 2011-03-31 Todd Ehrlich Dietary supplements in beverages or other forms, and methods of use and production
US9931381B2 (en) * 2009-11-23 2018-04-03 Prothera, Inc. Methods of comprising serratia peptidase for inhibition and treatment of biofilms related to certain conditions
US9011909B2 (en) 2010-09-03 2015-04-21 Wisconsin Pharmacal Company, Llc Prebiotic suppositories
US20120070423A1 (en) * 2010-09-21 2012-03-22 Puneet Nanda Oral composition and method of forming and using same
US9198957B2 (en) 2011-01-31 2015-12-01 The Trustees Of Columbia University In The City Of New York Treatment and prevention of bacterial vaginosis and Gardnerella vaginalis infections
CN111518866A (zh) * 2011-03-01 2020-08-11 群体创新有限责任公司 用于治疗与致病生物膜相关之病症的材料和方法
US20120315260A1 (en) * 2011-06-13 2012-12-13 Svetlana A. Ivanova Compositions and Methods to Prevent and Treat Biofilms
US10420822B2 (en) 2011-06-13 2019-09-24 Ziolase, Llc Compositions and methods to prevent and treat biofilms
GB201208879D0 (en) 2012-05-21 2012-07-04 London School Hygiene & Tropical Medicine Therapeutic for treating Clostridium difficile infection
WO2014130007A1 (en) * 2013-02-19 2014-08-28 Deerland Enzymes, Inc. Proteolytic compositions for rapidly and extensively degrading protein supplements
US12364738B2 (en) * 2016-06-08 2025-07-22 Onelife S.A. Composition comprising at least one enzyme and at least one microbicidal molecule for the prevention or treatment of post-implant infections
CA3055915A1 (en) * 2017-03-10 2018-09-13 Biohm Health Llc Compositions and methods for disrupting biofilms of pathogenic bacteria or fungi
CN108359696A (zh) * 2018-02-28 2018-08-03 苏州昆蓝生物科技有限公司 一种低聚木糖的制备方法
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
CN118252181A (zh) * 2024-05-30 2024-06-28 中国农业科学院北京畜牧兽医研究所 一种用于杀灭沙门氏菌的复合酶系及其应用
CN120093994A (zh) * 2025-03-07 2025-06-06 大连医科大学 一种纤维素酶在降解细菌生物膜中的应用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994390A (en) * 1989-03-13 1991-02-19 Nalco Chemical Company Enzyme blend containing cellulase to control industrial slime
US5389369A (en) * 1991-02-21 1995-02-14 Exoxemis, Inc. Halo peroxidase containing compositions for killing yeast and sporular microorganisms
US5260074A (en) * 1992-06-22 1993-11-09 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
US5861271A (en) * 1993-12-17 1999-01-19 Fowler; Timothy Cellulase enzymes and systems for their expressions
US5436003A (en) * 1994-02-10 1995-07-25 Triarco Industries, Inc. Method of alleviating gastrointestinal distress with a composition containing beta-fructofuransidase, cellulase and hemi-cellulase
GB9409336D0 (en) * 1994-05-10 1994-06-29 Finnfeeds Int Ltd Use of an enzyme for manufacturing an agent for the treatment and/or prophylaxis of coccidiosis
ATE210180T1 (de) * 1995-01-26 2001-12-15 Novozymes As Xylanase beinhaltende futterzusätze für tiere
EP0820516B1 (en) 1995-04-07 2002-03-06 BetzDearborn, Inc. Exopolysaccharide degrading enzyme and use of the same
US6365208B1 (en) * 1995-06-29 2002-04-02 Mcneil-Ppc, Inc. Stable lactase tablets
CN1201373A (zh) * 1995-11-06 1998-12-09 诺沃挪第克公司 动物饲料添加剂
US6599714B1 (en) * 1996-03-13 2003-07-29 University Technologies International Inc. Method of growing and analyzing a biofilm
US6100080A (en) * 1996-12-18 2000-08-08 Novo Nordisk A/S Method for enzymatic treatment of biofilm
GB2327345B (en) * 1997-07-18 1999-06-23 Finnfeeds Int Ltd Use of an enzyme for manufacturing an agent for controlling bacterial infection
US6756489B1 (en) * 1997-08-08 2004-06-29 Aventis Pharma Deutschland Gmbh Substituted tetrahydropyrane derivatives, method for producing same, their use as medicine or diagnostic agent, as well as medicine containing same
US6759040B1 (en) 1997-09-12 2004-07-06 University Of Maryland, College Park Preparation and use of biofilm-degrading, multiple-specificity, hydrolytic enzyme mixtures
US6830745B1 (en) * 1997-10-16 2004-12-14 Pharmacal Biotechnologies, Llc Compositions for treating biofilm
US20020037260A1 (en) * 1997-10-16 2002-03-28 Budny John A. Compositions for treating biofilm
ITMI981148A1 (it) * 1998-05-22 1999-11-22 Therapicon Srl Utilizzo di lisozima c modificato per preparare composizioni medicinali per il trattamento di alcune gravi malattie
ES2237121T3 (es) * 1998-07-28 2005-07-16 Takeda Pharmaceutical Company Limited Preparacion solida disgregable rapidamente.
JP2000226335A (ja) * 1998-12-04 2000-08-15 Amano Pharmaceut Co Ltd 経口用酵素製剤、酵素含有食材及び酵素製剤の服用方法
US7153503B1 (en) * 1998-12-19 2006-12-26 Janeel Henderson Comprehensive dietary supplement
EP1068871A1 (en) * 1999-07-07 2001-01-17 Jean-Paul Perraudin Novel methods and medicament for treating infections diseases involving microbial biofilms
CA2284103A1 (en) * 1999-09-30 2001-03-30 Edith Bonnelye Estrogen related receptor, err.alpha., a regulator of bone formation
UA78486C2 (uk) * 1999-12-10 2007-04-10 Хемджен Корпорейшн Композиція для перорального введення птахам та тваринам для лікування або зниження ризику інфекції травного тракту (варіанти), її застосування (варіанти) та спосіб лікування або зниження ризику інфекцій травного тракту (варіанти)
IL133851A (en) 1999-12-31 2002-12-01 Smoler Feed Additives And Tech Dietary supplement for animals
US6855548B2 (en) * 2000-02-08 2005-02-15 F. Hoffman-La Roche Ag Use of acid-stable proteases in animal feed
JP2001325067A (ja) 2000-05-17 2001-11-22 Ricoh Co Ltd 筆記情報処理装置と筆記情報処理システム及び情報記録媒体
US20040170617A1 (en) * 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
US20020013270A1 (en) 2000-06-05 2002-01-31 Bolte Ellen R. Method for treating a mental disorder
US20040062757A1 (en) * 2001-06-05 2004-04-01 Finegold Sydney M. Method of testing gastrointestinal diseases associated with species of genus clostridium
US6777223B2 (en) * 2000-06-19 2004-08-17 Novozymes Biotech, Inc. Methods for eliminating the formation of biofilm
US6716813B2 (en) * 2000-11-28 2004-04-06 House Ear Institute Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
CA2442685A1 (en) * 2001-04-04 2002-10-17 Edith Bonnelye Estrogen receptor-related receptor alpha (err.alpha.) and cartilage formation
AU2002307448A1 (en) * 2001-04-20 2002-11-05 President And Fellows Of Harvard College Methods and compositions for the modulation of biofilm formation
US20030099626A1 (en) * 2001-11-20 2003-05-29 Health Education Corporation Nutrient absorption enhancing compositions and methods
US8541472B2 (en) * 2001-12-05 2013-09-24 Aseptica, Inc. Antiseptic compositions, methods and systems
WO2003059302A1 (en) * 2002-01-03 2003-07-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem Edible compositions capable of removing oral biofilm
AU2003237789A1 (en) * 2002-03-26 2003-10-13 Biosynexus, Incorporated Enzyme disruption of bacterial biofilms
WO2003087464A1 (en) * 2002-04-05 2003-10-23 Novozymes North America, Inc. Improvement of strength and abrasion resistance of durable press finished cellulosic materials
US20040005304A1 (en) * 2002-07-08 2004-01-08 Mak Wood, Inc. Novel compositions and methods for treating neurological disorders and associated gastrointestinal conditions
DE10237317B4 (de) * 2002-08-15 2010-04-08 3M Espe Ag Enzymhaltige Zusammensetzung, Verfahren zu deren Herstellung und deren Verwendung
US6900173B2 (en) * 2002-09-11 2005-05-31 Kenneth A. Martin Perioperative multivitamin protein bar for use in preparing an individual for fast surgical recovery
US20050079594A1 (en) * 2002-10-31 2005-04-14 Karine Marion Method of removing a biofilm
NZ555378A (en) * 2002-12-20 2008-10-31 Univ New Jersey Med Compositions and methods for enzymatic detachment of bacterial and fungal biofilms
WO2004066945A2 (en) * 2003-01-24 2004-08-12 Diversa Corporation Enzymes and the nucleic acids encoding them and methods for making and using them
US6692726B1 (en) * 2003-02-11 2004-02-17 Colgate Palmolive Company Enzyme containing oral composition having enhanced stability
US7067124B2 (en) * 2003-03-28 2006-06-27 National Enzyme Company Protease composition and method for treating a digestive disorder
US7700544B2 (en) * 2003-06-12 2010-04-20 Queens's University At Kingston Compositions and methods for treating atherosclerosis
JP2007500697A (ja) * 2003-07-28 2007-01-18 デイビッド・ケイ・アール・カラオリス 微生物病原体の毒性を減弱させる方法、および微生物のバイオフィルム形成を阻害する方法
US7749509B2 (en) * 2003-08-29 2010-07-06 Cobb And Company, Llp Treatment of autism using probiotic composition
US7731976B2 (en) * 2003-08-29 2010-06-08 Cobb And Company, Llp Treatment of irritable bowel syndrome using probiotic composition
US7759105B2 (en) * 2003-08-29 2010-07-20 Cobb & Company, Llp Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US20060177424A1 (en) * 2003-08-29 2006-08-10 Cobb Mark L Treatment of disease states and adverse physiological conditions utilizing anti-fungal compositions
US8685374B2 (en) * 2003-09-12 2014-04-01 Ray And Terry's Health Products, Inc. EDTA containing compositions and uses thereof
US20060083727A1 (en) * 2004-07-15 2006-04-20 Nanobac Pharmaceuticals, Inc. Methods and compositions for the treatment of diseases characterized by calcification and/or plaque formation
US7691418B2 (en) * 2004-09-17 2010-04-06 Oystershell Nv Composition for inhibiting or preventing the formation of a biofilm
US9023323B2 (en) * 2004-12-16 2015-05-05 Colgate-Palmolive Company Oral compositions for prevention and reduction of bacterial adhesion to oral surfaces
US20060140881A1 (en) * 2004-12-22 2006-06-29 Guofeng Xu Oral care compositions containing flavonoids and flavans
US20070020237A1 (en) * 2005-06-01 2007-01-25 Biotech Institute For International Innovation, Inc. Glucose inducible insulin expression and methods of treating diabetes
US8512724B2 (en) * 2005-06-10 2013-08-20 The Board Of Regents Of The University Of Texas System Antiseptic compositions
DE102005049649A1 (de) * 2005-10-18 2007-04-19 Pro Natura Gesellschaft für gesunde Ernährung mbH Zusammensetzung zur Linderung von Beschwerden des Magen-Darm-Trakts
US20090175842A1 (en) * 2006-07-11 2009-07-09 Chandrakant Laxminarayan Rathi Dietary anti-bacterial compositions
US20080019956A1 (en) * 2006-07-24 2008-01-24 Manoj Kumar Enzymatic prevention and control of biofilm
US9931381B2 (en) * 2009-11-23 2018-04-03 Prothera, Inc. Methods of comprising serratia peptidase for inhibition and treatment of biofilms related to certain conditions

Also Published As

Publication number Publication date
PT2254591T (pt) 2017-11-10
US11078516B2 (en) 2021-08-03
NO2254591T3 (enExample) 2017-12-23
ES2645062T3 (es) 2017-12-04
US20090202516A1 (en) 2009-08-13
US20180258460A1 (en) 2018-09-13
JP6244291B2 (ja) 2017-12-06
EP2254591A2 (en) 2010-12-01
JP2011511809A (ja) 2011-04-14
WO2009100456A3 (en) 2009-12-03
DK2254591T3 (da) 2017-11-06
EP2254591B1 (en) 2017-07-26
PL2254591T3 (pl) 2018-01-31
EP2254591A4 (en) 2012-09-12
US20210332409A1 (en) 2021-10-28
JP6047273B2 (ja) 2016-12-21
JP2015110559A (ja) 2015-06-18
WO2009100456A2 (en) 2009-08-13

Similar Documents

Publication Publication Date Title
US11078516B2 (en) Inhibition and treatment of gastrointestinal biofilms
US9358274B2 (en) Methods comprising serratia peptidase for inhibition and treatment of biofilms related to certain conditions
Liu et al. Antimicrobial activity and virulence attenuation of citral against the fish pathogen Vibrio alginolyticus
US10758596B2 (en) Compositions and methods to prevent and treat biofilms
Devi et al. Inhibition of quorum sensing-mediated virulence in Serratia marcescens by Bacillus subtilis R-18
van Tilburg Bernardes et al. Current research approaches to target biofilm infections
CA3088187A1 (en) Compositions and methods to prevent and treat biofilms
Rocha et al. Ecological, beneficial, and pathogenic functions of the type 9 secretion system
Abinaya et al. Anti-quorum sensing activity of selected cationic amino acids against Chromobacterium violaceum and Pseudomonas aeruginosa
Gharat et al. Enhancing the destruction of Burkholderia cepacia biofilm on stainless steel coupons by combining matrix-degrading enzymes with antimicrobials
Adeyemi et al. Multidrug-resistant Pseudomonas aeruginosa isolates with virulence traits from wound samples exhibited low in-vitro susceptibility to honey, a viable alternative for the management of chronic wounds
Guchhait et al. Modern therapeutic strategies to mitigate biofilm-associated infection in livestock organisms
KR20200139458A (ko) 메틸 갈레이트 및 틸로신을 포함하는 항균용 조성물
Wang Evaluation of the activity of antibiotics and adjuvant strategies against dual species biofilms in the context of cystic fibrosis
Jamal The Effect of some Plant Extracts and Nano-compounds on Bacterial Quorum Sensing and Biofilm Formation on some Medical Devices
Leitgeb et al. Enzymatic and Antimicrobial Activity of Biologically Active Samples from Aloe arborescens and Aloe barbadensis. Biology 2021, 10, 765

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140128

FZDE Discontinued

Effective date: 20221122